Free tool
FAERS Monitor: Uptravi
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 214275 or its brand name (Uptravi, Selexipag). Reports on generic versions are filed under their own applications.
Reports
26,100
Serious
19,535
75% of reports
Hospitalization
12,787
Death reported
4,907
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- headache6,834
- diarrhoea5,244
- dyspnoea4,841
- nausea4,153
- fatigue2,651
- death2,559
- pain in jaw2,455
- dizziness2,338
- pain2,250
- pain in extremity2,149
- myalgia2,008
- vomiting1,970
- pneumonia1,832
- malaise1,818
- hypotension1,748
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2012 | 2 |
| 2013 | 2 |
| 2014 | 5 |
| 2015 | 26 |
| 2016 | 1,557 |
| 2017 | 2,388 |
| 2018 | 3,027 |
| 2019 | 3,219 |
| 2020 | 3,248 |
| 2021 | 2,807 |
| 2022 | 2,261 |
| 2023 | 2,301 |
| 2024 | 2,240 |
| 2025 | 1,807 |
| 2026 | 1,210 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,028,059 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| pain in jawSignal | 2,455 | 76.4 | 73.4 | 166,945 |
| myalgiaSignal | 2,008 | 9.6 | 9.2 | 15,442 |
| headacheSignal | 6,834 | 8.9 | 8.7 | 48,641 |
| hypotensionSignal | 1,748 | 7.1 | 6.8 | 9,120 |
| dyspnoeaSignal | 4,841 | 6.9 | 6.8 | 25,081 |
| diarrhoeaSignal | 5,244 | 6.6 | 6.4 | 25,450 |
| pain in extremitySignal | 2,149 | 5.9 | 5.7 | 8,828 |
| pneumoniaSignal | 1,832 | 4.6 | 4.4 | 5,174 |
| nauseaSignal | 4,153 | 4.2 | 4.1 | 10,648 |
| dizzinessSignal | 2,338 | 3.8 | 3.6 | 4,894 |
| vomitingSignal | 1,970 | 3.4 | 3.2 | 3,372 |
| malaiseSignal | 1,818 | 3.4 | 3.2 | 3,046 |
| painSignal | 2,250 | 3.0 | 2.8 | 2,993 |
| fatigueSignal | 2,651 | 2.7 | 2.7 | 3,053 |
| deathSignal | 2,559 | 2.4 | 2.3 | 2,166 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.